Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Laboratory methods for analyzing monoclonal proteins

S Vincent Rajkumar, MD
Section Editor
Robert A Kyle, MD
Deputy Editor
Rebecca F Connor, MD


The monoclonal gammopathies (paraproteinemias or dysproteinemias) are a group of disorders characterized by the proliferation of a single clone of plasma cells, which produces an immunologically homogeneous protein commonly referred to as a paraprotein or monoclonal protein (M-protein, where the "M" stands for monoclonal). (See 'Definition of an M-protein' below.)

A complete immunoglobulin consists of two heavy polypeptide chains of the same class designated by a capital letter and a corresponding Greek letter:

Gamma in IgG

Alpha in IgA

Mu in IgM

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Sep 22, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Katzmann JA, Kyle RA. Immunochemical characterization of immunoglobulins in serum, urine, and cerebrospinal fluid. In: Manual of Molecular and Clinical Laboratory Immunology, 7th ed, Detrick B (Ed), American Society for Microbiology Press, Washington, DC 2006. p.88.
  2. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147:22.
  3. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108:2520.
  4. Berth M, Delanghe J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg 2004; 59:263.
  5. Smogorzewska A, Flood JG, Long WH, Dighe AS. Paraprotein interference in automated chemistry analyzers. Clin Chem 2004; 50:1691.
  6. Tsai LY, Tsai SM, Lee SC, Liu SF. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. Clin Chim Acta 2005; 358:192.
  7. Pantanowitz L, Horowitz GL, Upalakalin JN, Beckwith BA. Artifactual hyperbilirubinemia due to paraprotein interference. Arch Pathol Lab Med 2003; 127:55.
  8. Murali MR, Kratz A, Finberg KE. Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol. N Engl J Med 2006; 355:2772.
  9. Krish P, Jhaveri KD. The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia. Kidney Int 2012; 81:603.
  10. Alyanakian MA, Taes Y, Bensaïd M, et al. Monoclonal immunoglobulin with antitransferrin activity: A rare cause of hypersideremia with increased transferrin saturation. Blood 2007; 109:359.
  11. Katzmann JA, Clark R, Wiegert E, et al. Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis 1997; 18:1775.
  12. Katzmann JA, Clark R, Sanders E, et al. Prospective study of serum protein capillary zone electrophoresis and immunotyping of monoclonal proteins by immunosubtraction. Am J Clin Pathol 1998; 110:503.
  13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.
  14. Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 1981; 71:999.
  15. Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76:476.
  16. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180.
  17. Amara S, Dezube BJ, Cooley TP, et al. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 2006; 43:1198.
  18. Yee TT, Murphy K, Johnson M, et al. Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection. Am J Hematol 2001; 66:123.
  19. Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read 2004; 14:372.
  20. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.
  21. Pola V, Tichý M. [Bisalbuminemia. Critical review and report of a case of an acquired form in a myeloma patient]. Folia Haematol Int Mag Klin Morphol Blutforsch 1985; 112:208.
  22. Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and "Mediterranean" lymphomas. Springer Semin Immunopathol 1990; 12:239.
  23. Seligmann M, Mihaesco E, Preud'homme JL, et al. Heavy chain diseases: current findings and concepts. Immunol Rev 1979; 48:145.
  24. Fermand JP, Brouet JC. Heavy-chain diseases. Hematol Oncol Clin North Am 1999; 13:1281.
  25. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105:2274.
  26. Wahner-Roedler DL, Kyle RA. Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol 1992; 40:56.
  27. Fermand JP, Brouet JC, Danon F, Seligmann M. Gamma heavy chain "disease": heterogeneity of the clinicopathologic features. Report of 16 cases and review of the literature. Medicine (Baltimore) 1989; 68:321.
  28. Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore) 2003; 82:236.
  29. Kyle RA, Greipp PR. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.
  30. Grosbois B, Jégo P, de Rosa H, et al. [Triclonal gammopathy and malignant immunoproliferative syndrome]. Rev Med Interne 1997; 18:470.
  31. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437.
  32. Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706.
  33. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900.
  34. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489.
  35. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008; 141:413.
  36. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119:274.
  37. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78.
  38. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348.
  39. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110:827.
  40. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81:1575.
  41. Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009; 131:166.
  42. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1684.
  43. Vermeersch P, Van Hoovels L, Delforge M, et al. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 2008; 143:496.
  44. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008; 93:459.
  45. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995; 10:128.
  46. Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 1991; 28 ( Pt 3):253.
  47. Sinclair D, Ballantyne F, Shanley S, et al. Estimation of paraproteins by immunoturbidimetry and electrophoresis followed by scanning densitometry. Ann Clin Biochem 1990; 27 ( Pt 4):335.
  48. Harrison HH. The "ladder light chain" or "pseudo-oligoclonal" pattern in urinary immunofixation electrophoresis (IFE) studies: a distinctive IFE pattern and an explanatory hypothesis relating it to free polyclonal light chains. Clin Chem 1991; 37:1559.